证券代码：301520 证券简称：万邦医药 公告编号：2025-016 安徽万邦医药科技股份有限公司 关于 2025 年度董事、监事、高级管理人员薪酬方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 根据《安徽万邦医药科技股份有限公司章程》《安徽万邦医药科技股份有限公司 薪酬与考核委员会工作细则》等公司相关制度，结合安徽万邦医药科技股份有限公司 （以下简称"公司"）经营规模等实际情况并参照行业薪酬水平，公司制定了2025年 度董事、监事、高级管理人员薪酬方案，并经2025年4月18日召开的第二届董事会第 十七次会议及第二届监事会第十一次会议，分别审议了《关于公司董事2025年度薪酬 方案的议案》《关于公司高级管理人员2025年度薪酬方案的议案》《关于公司监事 2025年度薪酬方案的议案》。其中《关于公司董事2025年度薪酬方案的议案》《关于 公司监事2025年度薪酬方案的议案》因全体董事、监事回避表决，直接提交公司股东 大会审议。现将相关情况公告如下： 一、适用对象及期限 适用对象：公司2025年度任期内的董事、监事、高级管理人员 适用期限：2025 ...

关于召开公司 2024 年年度股东大会的通知 证券代码：301520 证券简称：万邦医药 公告编号：2025-022 安徽万邦医药科技股份有限公司 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年5月13日 9:15至15:00期间的任意时间。 1. 股东大会届次：2024年年度股东大会 2. 股东大会的召集人：公司董事会 3. 会议召开的合法、合规性：本次股东大会会议的召开符合《中华人民共 和国公司法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》 和《公司章程》等相关规定。 4. 会议召开的日期和时间： （1）现场会议召开时间：2025年5月13日（星期二）14:00。 （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月13日 9:15-9:25，9:30-11:30，13:00-15:00； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日 召开第二届董事会第十七次会议，审议通过了《关于召开公司 2024 年年 ...

安徽万邦医药科技股份有限公司 证券代码：301520 证券简称：万邦医药 公告编号：2025-015 第二届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 安徽万邦医药科技股份有限公司（以下简称"公司"）第二届监事会第十一 次会议（以下简称"本次会议"）的会议通知已于2025年4月8日以通讯方式发出， 本次会议于2025年4月18日12:00在安徽省合肥市高新区火龙地路299号218会议 室以现场方式结合通讯方式召开。本次会议应出席监事3名，实际出席监事3名， 董事会秘书列席。会议由公司监事会主席王小董先生召集和主持。本次会议的召 集、召开和表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等 相关法律法规和《安徽万邦医药科技股份有限公司章程》（以下简称"《公司章程》"） 的规定。 二、监事会会议审议情况 （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 经审议，监事会认为：公司董事会编制和审议《2024 年年度报告》全文及其 摘要的程序符合法律法规及中国证监会的规定，报告内容真实、准 ...

证券代码：301520 证券简称：万邦医药 公告编号：2025-014 安徽万邦医药科技股份有限公司 第二届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 安徽万邦医药科技股份有限公司（以下简称"公司"）第二届董事会第十七 次会议（以下简称"本次会议"）的会议通知已于2025年4月8日以通讯方式发出， 本次会议于2025年4月18日11:00在安徽省合肥市高新区火龙地路299号218会议 室以现场方式召开。本次会议应出席董事6名，实际出席董事6名。会议由公司董 事长陶春蕾女士主持，公司监事及高级管理人员列席会议。本次会议的召集、召 开和表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等相关法 律法规和《安徽万邦医药科技股份有限公司章程（以下简称"《公司章程》"）》的 规定。 二、董事会会议审议情况 （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 经审议，董事会认为：公司《2024 年年度报告》全文及其摘要的内容真实、 准确、完整地反映了公司 2024 年度经营的实际情况，不存在任何 ...

证券代码：301520 证券简称：万邦医药 公告编号：2025-017 安徽万邦医药科技股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、2024年度利润分配预案基本情况 1、本次利润分配预案的内容 经容诚会计师事务所（特殊普通合伙）审计，并出具标准无保留意见审计报告确 认，2024 年度归属于母公司所有者的净利润为 85,530,677.51 元，其中母公司实现净 利润 74,529,847.67 元，根据《公司法》和《公司章程》的有关规定，以母公司 2024 年度净利润为基数，按 10%计提法定盈余公积 7,452,984.77 元。截至 2024 年 12 月 31 日，公司合并报表未分配利润为 371,593,963.69 元；母公司未分配利润为 323,234,166.44 元。按照合并报表、母公司报表中可供分配利润孰低原则，公司可供 股东分配利润为 323,234,166.44 元。 公司 2024 年度拟不派发现金红利、不送红股、不以资本公积金转增股本，未分 配利润结转下年度。 公司本次 ...

Financial Performance - The company's revenue for Q1 2025 was ¥71,052,156.02, a decrease of 21.20% compared to ¥90,172,342.02 in the same period last year[5] - Net profit attributable to shareholders was ¥11,849,289.05, down 60.09% from ¥29,687,084.26 year-on-year[5] - Basic earnings per share decreased by 60.00% to ¥0.18 from ¥0.45 in the previous year[5] - The company reported a 76.44% decrease in net profit after deducting non-recurring gains and losses, amounting to ¥5,358,872.31 compared to ¥22,744,459.46 in the same period last year[5] - Total operating revenue for the current period is ¥71,052,156.02, a decrease of 21.2% compared to ¥90,172,342.02 in the previous period[23] - Net profit for the current period is ¥11,849,289.05, down 60.0% from ¥29,687,084.26 in the previous period[24] - Operating profit decreased significantly to ¥11,769,736.76 from ¥32,127,485.39, a decline of 63.4%[24] - Total comprehensive income for the period was CNY 11,849,289.05, compared to CNY 29,687,084.26 in the previous period[25] - Basic and diluted earnings per share were both CNY 0.18, down from CNY 0.45 in the previous period[25] Cash Flow - The net cash flow from operating activities was -¥16,868,485.59, a significant decline of 3,079.21% compared to ¥566,206.01 in Q1 2024[5] - Cash inflow from operating activities totaled CNY 55,460,356.38, down from CNY 77,696,322.08 in the previous period[27] - Cash outflow from operating activities was CNY 72,328,841.97, compared to CNY 77,130,116.07 in the previous period[28] - Cash flow from investing activities generated a net inflow of CNY 16,193,260.48, compared to a net outflow of CNY -15,317,843.65 in the previous period[28] - Cash and cash equivalents at the end of the period were CNY 151,823,897.33, down from CNY 238,745,336.87 at the end of the previous period[28] - Total cash inflow from investment activities was CNY 690,905,762.96, with cash outflow of CNY 674,712,502.48[28] - The company did not report any cash inflow from financing activities during the period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,576,204,060.70, down 1.72% from ¥1,603,808,014.06 at the end of the previous year[5] - The company’s total liabilities decreased by 1.04% to ¥1,497,621,339.19 from ¥1,513,368,506.60 at the end of the previous year[5] - Total liabilities decreased to ¥78,582,721.51 from ¥90,439,507.46, a reduction of 13.1%[22] - The company reported a decrease in accounts payable, which rose to ¥39,620,377.34 from ¥37,833,222.06, an increase of 4.7%[22] - The company's cash and cash equivalents decreased from ¥179,294,435.57 to ¥151,823,897.33, representing a decline of approximately 15.3%[20] - The trading financial assets slightly decreased from ¥1,023,470,174.93 to ¥1,006,075,052.63, a reduction of about 1.7%[20] - Accounts receivable increased from ¥63,892,072.37 to ¥67,744,481.69, showing a growth of approximately 6.0%[20] - The prepayments rose from ¥9,942,873.55 to ¥10,840,590.77, indicating an increase of around 9.0%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,256[14] - The company has a total of 44,243,675 shares under lock-up, with the majority set to be released on March 25, 2027[18] - The top shareholder, Tao Chunlei, holds 26,427,800 shares, which are subject to lock-up until March 25, 2027[17] - The company reported no changes in the number of restricted shares during the period[17] - The top ten shareholders include significant holdings from various investment partnerships, indicating a diverse ownership structure[18] Operational Insights - The company experienced a significant increase in investment income, which rose by 216.37% to ¥2,149,076.26 from ¥679,300.01 year-on-year[11] - The cash flow from investing activities improved to ¥16,193,260.48, a 205.72% increase compared to -¥15,317,843.65 in Q1 2024[13] - Research and development expenses for the current period are ¥10,765,309.15, slightly up from ¥10,738,916.39 in the previous period[24] - Deferred income tax liabilities increased slightly to ¥8,371,304.41 from ¥8,310,227.58, an increase of 0.7%[22] - The company has not engaged in any new mergers or acquisitions during the reporting period[19] - There are no new product launches or technological advancements reported in the latest earnings call[19] Audit Status - The first quarter report was not audited[29]

Financial Performance - The company's revenue for 2024 reached ¥379,090,705.99, representing a 10.91% increase compared to ¥341,806,532.85 in 2023[22]. - Net profit attributable to shareholders decreased by 20.87% to ¥85,530,677.51 in 2024 from ¥108,091,849.31 in 2023[22]. - The net profit after deducting non-recurring gains and losses fell by 42.90% to ¥55,787,750.40 in 2024 compared to ¥97,695,165.41 in 2023[22]. - Operating cash flow net amount decreased by 34.87% to ¥46,841,483.75 in 2024 from ¥71,924,782.54 in 2023[22]. - Basic and diluted earnings per share both dropped by 36.00% to ¥1.28 in 2024 from ¥2 in 2023[22]. - The total assets at the end of 2024 were ¥1,603,808,014.06, a 3.83% increase from ¥1,544,589,389.03 at the end of 2023[22]. - The net assets attributable to shareholders increased by 3.37% to ¥1,513,368,506.60 at the end of 2024 from ¥1,464,009,758.59 at the end of 2023[22]. - The total operating revenue for 2024 reached ¥379,090,705.99, representing a year-on-year increase of 10.91% compared to ¥341,806,532.85 in 2023[58]. - Clinical research services accounted for 80.11% of total revenue, with a significant increase of 24.62% year-on-year, amounting to ¥303,671,717.70[58]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and development strategies[5]. - The management discussion section outlines potential risks in the company's operations[5]. - The company faces risks related to innovation and technology, as it must continuously meet the increasing technical demands of clients in the pharmaceutical industry[99]. - Regulatory changes in drug approval processes pose a risk to the company's operations, as stricter compliance with national standards is required for drug research and development[100]. - The company is highly dependent on the pharmaceutical industry's R&D investments, which have been increasing due to government support, but any slowdown in the pharmaceutical sector could negatively impact business[101][102]. - The company is in a growth phase with limited market risk resilience, and various factors such as policy changes and competition could affect performance[103]. - The gross margin is subject to fluctuations due to the customized nature of services and market conditions, which may lead to risks in maintaining high gross margins[104]. Corporate Governance - The financial report is guaranteed to be true, accurate, and complete by the board of directors and management[5]. - The company has a governance structure in place, including a board of directors and various committees, ensuring compliance with legal and regulatory requirements[109][111]. - The company held three shareholder meetings during the reporting period, ensuring fair treatment of all investors, especially minority shareholders[110]. - The company maintains independence from its controlling shareholders in terms of assets, personnel, and operations, adhering to regulatory guidelines[115]. - The company has established an independent financial department with a standardized financial accounting system and independent bank accounts, ensuring no shared accounts with actual controllers or related enterprises[118]. - The audit committee ensured compliance with the Company Law and internal audit procedures, with no dissenting opinions recorded[144]. - The board members actively contributed to major decision-making processes, ensuring the scientific and reasonable nature of company decisions[142]. Employee Management - The company employed a total of 478 staff, with 86.19% being technical personnel, indicating a strong talent pool[55]. - The company emphasizes a competitive salary structure to attract and retain talent, aligning compensation with performance evaluations[149]. - The company aims to enhance employee training and development, focusing on leadership and internal training programs[150]. - The company has established a comprehensive employee incentive mechanism, including performance assessments and a project reward system to encourage innovation and technical breakthroughs[164]. - The company has signed labor contracts with employees in accordance with the Labor Law and Labor Contract Law of the People's Republic of China, providing social security benefits such as basic pension and medical insurance[164]. Strategic Development - The company is focused on expanding its market presence and enhancing its product offerings[5]. - The company aims to transform from "pharmaceutical CRO" to "healthcare CRO," focusing on expanding its business scope and enhancing its international presence while maintaining its existing generic drug research and clinical study operations[96]. - The company plans to explore international markets, particularly in Europe, the United States, and Southeast Asia, to identify development opportunities and establish operational models[97]. - The company intends to enhance its core competitiveness through digital transformation and innovation, which is essential for its expansion and risk management[97]. - The company is focusing on the health industry ecosystem, particularly in anti-aging and functional health food sectors, while increasing investment in innovative projects to cultivate new growth avenues[98]. Financial Policies - The company plans not to distribute cash dividends, issue bonus shares, or increase capital using reserves[6]. - The company is committed to maintaining transparency in its financial disclosures[5]. - The company has established a dividend policy to ensure reasonable returns for all shareholders, particularly small shareholders[179]. - The company will adhere to its dividend policy to ensure shareholder returns, refining its profit distribution policy in line with regulatory requirements[178]. - The company has committed to timely disclosure of any unfulfilled commitments and will apologize to investors if necessary[182]. Research and Development - The company has a robust pipeline for drug development, focusing on market-driven research and technology transfer to clients[47]. - R&D expenses surged by 75.78% to ¥60,681,199.45, reflecting the company's commitment to increasing investment in research and development[67]. - The company increased R&D investment to ¥60,832,767.14 in 2024, representing 16.05% of operating revenue, up from 10.69% in 2023[71]. - The number of R&D personnel rose to 412 in 2024, a 5.91% increase from 389 in 2023, with a notable increase in master's degree holders by 46.15%[71]. - The company is advancing a key R&D project aimed at diabetes-related chronic kidney disease, with the goal of obtaining drug registration certification[68]. Internal Control and Compliance - The company has established a comprehensive and effective internal control system, ensuring compliance with accounting standards and risk management[156]. - There are no significant internal control deficiencies identified for the fiscal year 2024, both in financial and non-financial reporting[158]. - The internal control evaluation report indicates that 100% of the total assets and operating income of the evaluated units are included in the company's consolidated financial statements[158]. - The internal control audit report issued on April 18, 2025, confirms that the company maintained effective internal control over financial reporting as of December 31, 2024[160]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[162]. Shareholder Relations - The company has a lock-up period for stock holdings, with a commitment that any reduction in holdings after the lock-up will not be below the issuance price[167]. - The company and its major shareholders have committed to avoiding any business that competes with the company's existing operations[173]. - The commitment to avoid competition will remain effective as long as the major shareholders hold their positions[173]. - Shareholders are required to comply with relevant regulations regarding share reduction and must formulate prudent reduction plans[172]. - The company will adjust share prices in accordance with any dividend distributions or capital increases during the lock-up period[171].

4月9日，万邦医药今日收盘36.91元，上涨1.46%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到22.66倍，总市值24.61亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均45.77倍，行业中值43.78倍，万邦医药排 名第17位。 最新一期业绩显示，2024年三季报，公司实现营业收入2.93亿元，同比21.88%；净利润7779.75万元， 同比0.63%，销售毛利率43.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)17万邦医药22.6622.761.6324.61亿行业平均 45.7741.333.33140.72亿行业中值43.7835.472.4544.48亿1普瑞眼科-192.3424.042.9064.41亿2何氏眼 科-144.5344.311.4628.16亿3迪安诊断-92.5027.851.2185.62亿4光正眼科-84.88201.676.8418.66亿5创新医 疗-78.10-109.142.0337.42亿6南华生物-74.52-98.0511.1127.62亿7国际医学-32.76-31.853.21117.31亿8嘉和 ...

关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 安徽万邦医药科技股份有限公司（以下简称"公司"）于 2024 年 10 月 23 日 召开第二届董事会第十五次会议和第二届监事会第九次会议，审议通过了《关于 使用部分超募资金回购公司部分股份方案的议案》，同意公司使用超募资金以集 中竞价交易方式回购公司部分社会公众股股份并用于股权激励计划或员工持股 计划，用于回购股份的总金额为 1,500 万元-3,000 万元，回购价格不超过 60.62 元/股（含），具体回购股份的数量及金额以回购期满时实际回购的股份数量及金 额为准。本次回购的实施期限为董事会审议通过回购方案之日起 12 个月内。具 体内容详见公司于巨潮资讯网（www.cninfo.com.cn）上披露的《关于使用部分 超募资金回购公司部分股份方案的公告》（公告编号：2024-040）和《回购报告 书》（公告编号：2024-042）。 证券代码：301520 证券简称：万邦医药 公告编号：2025-011 安徽万邦医药科技股份有限公司 二、其他说明 公司回购股份的时间、回购股份数量及集 ...

3月27日，万邦医药今日收盘41.56元，上涨3.38%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到25.52倍，总市值27.71亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均44.44倍，行业中值43.69倍，万邦医药排 名第17位。 资金流向方面，3月27日，万邦医药主力资金净流入536.33万元，近5日总体呈流出状态，5日共流出 387.18万元。 安徽万邦医药科技股份有限公司主营业务是为医药企业和其他医药研发机构提供专业化医药研发外包服 务。公司的服务主要分为药学研究服务和临床研究服务两大类。近年来，公司获得了高新技术企业、中 国医药外包公司20强、中国医药守法诚信企业、合肥高新区瞪羚企业、安徽省企业技术中心、安徽省专 精特新中小企业等多个荣誉称号。 最新一期业绩显示，2024年三季报，公司实现营业收入2.93亿元，同比21.88%；净利润7779.75万元， 同比0.63%，销售毛利率43.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)17万邦医药25.5225.631.8427.71亿行业平均 44.4436.563.80166.76亿行业中值4 ...